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Gliomas are the most common primary brain tumor affecting human adults and remain a 
therapeutic challenge because cells of origin are still unknown. Here, we investigated the 
cellular origin of low-grade gliomas in a rat model based on transplacental exposure to N-
ethyl-N-nitrosourea  (ENU).  Longitudinal  magnetic  resonance  imaging  coupled  to 
immunohistological and immunocytochemical analyses were used to further characterize 
low-grade rat gliomas at different stages of evolution. We showed that early low-grade 
gliomas  have  characteristics  of  oligodendroglioma-like  tumors  and  exclusively  contain 
NG2-expressing  slow  dividing  precursor  cells  which  express  early  markers  of 
oligodendroglial lineage. These tumor-derived precursors failed to fully differentiate into 
oligodendrocytes and exhibited multipotential abilities  in vitro. Moreover, a few glioma 
NG2+ cells  are  resistant to  radiotherapy and may be responsible  for tumor recurrence, 
frequently  observed  in  humans.  Overall,  these  findings  suggest  that  transformed 
multipotent NG2 glial precursor cell may be a potential cell of origin in the genesis of rat 
ENU-induced oligodendroglioma-like tumors. This work may open up new perspectives 
for understanding biology of human gliomas.











Glioma represent the most common and heterogeneous group of brain tumors emerging in 
adult human central nervous system. These tumors are traditionally classified according to 
their  histopathology  and  the  cell-type  markers  they  express  and  lead  to  a  complex 
classification  theme.  Nevertheless,  glioma  can  roughly  be  subdivided  into  three  major 
subgroups of  different  grades:  (1)  astrocytomas:  pilocytic  (grade  I),  diffuse  (grade  II), 
anaplastic  (grade  III)  and  glioblastoma  multiform  (GBM)  (grade  IV),  (2) 
oligodendrogliomas  (grade  II  and  grade  III),  and  (3)  mixed  oligoastrocytomas.  This 
diversity of glioma correlates with a wide spectrum of mutated or affected cell signaling 
pathways observed in these neoplasms and also likely due to their different ‘cell of origin’ 
[1]. Moreover, in many cases, tumors which share a similar morphology and phenotype 
may have very different prognoses and responses to therapies. This underlines the need to 
redefine the criterions of the tumor classification which now will have to deal not only 
with a molecular and cellular analysis of the tumor bulk, but also on a better understanding 
of how tumors  emerge,  evolve over time and what cell  types  they arise  from.  Several 
recent  studies  have  identified  a  tumorigenic  CD133+  subpopulation  of  cancer  cells 
regarded as tumor stem cells within GBM responsible for the initiation and development of 
those heterogeneous aggressive brain tumors  [2-5].  The presence of cancer stem cells in 
GBM may also explain the resistance of these tumors to radiotherapy and chemotherapy 
[6]. In contrast to glioblastomas,  oligodendrogliomas are more sensitive to radiotherapy 
and  alkylating  agent  chemotherapy  [7,8].  This  variable  therapeutic  responsiveness  has 
raised the hypothesis that oligodendroglioma and glioblastoma may have distinct origins. 
Transgenic  mouse  and rat  models  using controlled  ectopic  expression of  oncogenes  in 
either  precursor  or  maturing  astrocytes  have  been  used  to  model  human  glioblastoma, 
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astrocytomas,  oligodendrogliomas,  or  oligoastrocytomas,  depending  on  the  oncogenic 
stimuli  [9-16].  These  studies  highlight  the  potential  genetic  mutations  which  could  be 
responsible for tumor initiation and development. On the other hand, recent studies have 
shown that signals from environment can also initiate and mediate tumor growth, as nestin-
positive neonatal  neural  progenitors  retrovirally over-expressing PDGF-B generate  pure 
oligodendroglioma,  whereas  targeting  GFAP-expressing  glial  progenitors  gives  rise  to 
several types of tumors [17,18].  In order to complement these genetically-induced tumor 
studies, we here investigated the ‘cell of origin’ of low-grade glioma in a far known rat 
model which spontaneously develops glioma in response to transplacental exposure to the 
DNA alkylating agent N-ethyl-N-nitrosourea (ENU) [19-23]. ENU-induced tumors have 
morphological  and  biological  features  similar  to  human  glioma  [22,24].  ENU-induced 
tumors mimic the evolution and development of a brain tumor upon a sporadic exposure to 
carcinogens and neoplasms appear after several months of latency, thus helping with the 
understanding of early events occurring during gliomagenesis. In this study, we performed 
longitudinal MRI analysis of ENU-induced glioma over a period of 11 months combined 
with full characterization of tumor cells at different developmental stages. We identified a 
new slow dividing  NG2 cell  population,  expressing  early  markers  of  oligodendroglial 
lineage and compromised in their differentiation, in low-grade glioma. In vitro, these cells 
exhibited  multipotential  abilities.  In  postnatal/adult  brain  NG2-expressing  cells  are 
strongly  associated  with  fast  dividing  oligodendrocyte  progenitor  cells  (OPC)  [25]. 
However,  heterogeneity  of  NG2+  cell  population  has  been  demonstrated  in  several 
occasions.  Bouslama-Oueghlani  provided  evidence  that  two  types  of  NG2+  cells  are 
present in developing brain, one highly proliferating and able to myelinate axons, and one 
almost quiescent with a reduced ability to produce myelin [26].  Recent studies have also 
demonstrated that early postnatal NG2+ cells are able to form passageable neurospheres 
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and  to  differentiate  into  neurons  in  vitro [27]  as  well  as  to  contribute  to  postnatal 
neurogenesis in developing hippocampus and olfactory bulb [28,29]. We also previously 
found that NG2 marker is expressed in multipotent neurospheres derived from adult SVZ 
[30].  We propose a potential contribution of these multipotent NG2+ glial precursors in 
low-grade glioma genesis and recurrence. These findings may help to understand several 
features observed in human oligodendroglioma and to design new therapies to cure glioma.
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The following primary antibodies were used : IQGAP1 (H109, rabbit, 1/500e, Santa Cruz 
Biotechnology), Nestin (clone rat-401, mouse, 1/500e, Developmental Studies Hybridoma 
Bank), NG2 (mouse or rabbit, 1/500e, Upstate), Olig2 (rabbit, 1/500e, a generous gift from 
Dr.  H.  Chneiweiss,  INSERM  U114,  Paris),  GFAP (rabbit,  1/500e,  Dako  Cytomation), 
Sox10 (rabbit, 1/500e, a generous gift from Dr Wegner, Erlangen University, Germany), 
Nkx2.2  (mouse,  1/100e,  Developmental  Studies  Hybridoma  Bank),  A2B5 (mouse,  1/3, 
hybridoma production), O4 (mouse, 1/3, hybridoma production), βIII-tubuline (clone Tuj-
1, rabbit, 1/1000e, Eurogentec), Ki67 (mouse, 1/100e, AbCys), Collagen IV (goat, 1/1000e, 
Southern Biotech)
Secondary  antibodies  conjugated  to  cyanine  3  or  cyanine  5  were  from  Jackson 
Laboratories (Interchim, France), secondary antibodies conjugated to Alexa Fluo 488 were 
from Molecular Probes (Invitrogen, France) and biotinylated anti-goat secondary antibody 
was from Southern Biotech. 
Chemo-induced tumorigenesis
All  procedures  on  animals  were  approved by the  Rhône-Alpes  Committee  for  Animal 
Experimentation Ethics (CREEA). OFA Sprague-Dawley pregnant rats were obtained from 
Charles River Laboratories (France). Pregnant rats were injected i.v. via the tail vein with 
60mg/kg Ethylnitrosourea (Sigma-Aldrich) at gestational day E19. Five independent ENU 










Magnetic Resonance Imaging (MRI) of rat brains
MRI images were obtained with a 2.35T magnet using a volume coil for transmission and a 
surface coil for reception. Anesthetized rats were placed in a cradle and their head was 
maintained with ear bars and a bite bar. For each animal, 20 contiguous 1 mm-thick slices, 
were  acquired  using  a  T2-weighted  spin-echo  sequence  (TR/TE=2000/80ms, 
matrix=256*192 or 128*128, 2 accumulations, FOV=30x30 mm2).
Tumor Growth Profile
Tumor volume was calculated using Image J software. Tumor surface (mm2) was measured 
on MRI images according to MRI resolution. Tumor volume was calculated by analyzing 
the surface of the tumor on successive MRI slices multiplied by slice thickness (1 mm). 
Two-way Anova statistical analysis was done using Sigma Stat software. Holm-Sidak tests 
were used for post-hoc multiple comparisons.
Immunohistochemistry/immunofluorescence
3- to- 12-months old animals were deeply anesthetized with 5% isoflurane and killed by 
decapitation. Brains were immediately frozen in isopentane at -80°C. 10-μm cryosections 
were cut and postfixed in 4% paraformaldehyde. Sections were colored with hematoxylin 
and eosin for histological analysis. Alternatively, cryosections were permeabilized in TBS-
0.2% Triton and blocked in TBS-5% goat serum. After overnight incubation with primary 
antibodies,  sections  were  stained  with  secondary  antibodies  and  counterstained  with 
nuclear marker Hoechst 33258 (1μg/mL) when desired. Images were obtained with a Carl 
Zeiss Axiovert 200M microscope and with a Leica (TCS SP2) confocal microscope. 
Cells or glioma explants were fixed using 4% paraformaldehyde and procedures were the 
same as brain slices except that  incubation times for primary and secondary antibodies 
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were reduced to 1 hour each. Antibodies for cell surface markers, such as A2B5 and O4, 
were added to culture medium for 1h before cell fixation. 
Oligodendroglioma-derived cell culture
After MRI localization, tumors were excised from freshly dissected rat brains. They were 
cut in explants and plated onto poly-L-lysine treated glass coverslips, either in proliferation 
medium with 10ng/mL PDGF and 1 µg/mL bFGF, or in differentiation medium where 
PDGF and bFGF were replaced by 30ng/mL T3, 5ng/mL CNTF and 5μm Forskolin (as 
described in Deloulme et al. 2004 and Kondo and Raff 2000 [29]). After 4 to 8 days in 
culture, cells were fixed in 4% paraformaldehyde. Additionally, a piece of the tumor was 
frozen  in  isopentane  at  -80°C  immediately  after  dissection  for  immunohistological 
characterization.
Rat brain tumor irradiation
Irradiation  was  performed  at  the  Biomedical  beamline  of  the  European  Synchrotron 
Radiation  Facility  (ESRF).  Irradiation  was performed with monochromatic  synchrotron 
radiation, emitted from a wiggler multipole magnet. The energy used was 80 keV with a 
bandwidth of ΔE/E = 10-3. The dose delivered to tumors was 15 Gy. The irradiated volume 
covered a whole hemisphere and it was performed in tomotherapy mode, i.e. rotating the 
animal in the beam. The animals were anesthetized for irradiation and held vertically in a 
plastic frame, which kept their heads fixed. Beam dimensions were 1 mm vertical and 10 
mm  horizontal.  Therefore,  multistage  irradiations  were  performed  to  cover  the  total 
volume of the brain hemisphere, typically 15 mm in length and 10 mm in diameter.
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Spatial and temporal emergence and development of rat chemically-induced brain 
tumors. 
In this study, we used a well-established experimental model of brain tumors in which rats 
exposed  in  utero to  a  single  dose  of  a  mutagen,  the  N-Ethyl-N-NitrosoUrea  (ENU) 
preferentially  develop  brain  tumors  [19,22,24].  This  model  has  also  the  advantage  of 
retracing  basic  events  of  carcinogenesis  following  a  random exposure  to  mutagens  or 
chemicals. The latency before appearance of brain tumor enables to address early events 
occurring  in  brain  tumor  genesis.  Moreover,  the  drug is  rapidly degraded  in  vivo thus 
avoiding any side effects causing by inflammatory response [31]. Six months to eleven 
months after exposure, some exposed animals exhibited severe neurological symptoms and 
the post-mortem examination  revealed  the presence of peripheral  tumors  and/or  highly 
invasive brain tumors. These animals were no further investigated. We focused on exposed 
rats which showed no pathological evidence of tumor formation, hypothesizing that these 
might represent earliest stages in tumor occurrence. Longitudinal T2-weighted magnetic 
resonance  imaging  (MRI)  along  with  measurements  of  water  diffusion  (i.e  ADC  = 
Apparent Diffusion Coefficient) were used to visualize the spatial and temporal emergence 
of asymptomatic brain tumors. Several brain tumors within a single animal were frequently 
observed. At 6 months of age, asymptomatic brain tumors showed sizes ranging between 
250 µm3  to  1200 µm3  and exhibited  a  homogenous  hypersignal  on  T2-weighted  scans 
(Figure 1a-d).  Subsequently, 4 to 5 months later (i.e at 10-11 months of age) ENU-induced 
tumors evolved in different ways and allowed us to distinguish 3 tumor subtypes (Type 1 
to 3) according to MRI pictures (Figure 1 a-d), tumor growth profiles (Figure 1d) and 
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mitotic index (Figure 1e). Type 1 glioma (67%) and Type 2 glioma (17.5%) maintained a 
homogenous  hypersignal  on  T2-weighted  scans  (Figure  1a-b).  Type  1  gliomas  were 
characterized by a linear growth over time with a doubling volume every 2 to 3 months 
(Figure 1d).  Type 1 glioma mainly located in the corpus callosum (CC) (45%) and in 
germinative  areas  (30%)  including  the  anterior  subventricular  zone  and  the  rostral 
migratory stream (Supplemental  Figure 1a).  Type 2-induced glioma followed the same 
diagram (Figure 1b) but grew almost 3 times faster than types 1 to increase tenfold in size 
over a period of 5 months (Figure 1d). Type 2 glioma were predominantly located in the 
corpus callosum (29%) and the cortex (33%) (Supplemental  Figure 1b). Type 3 glioma 
(15%) adopted a 2 phase-pattern, with a slow growth for the first 9 months followed by an 
exponential  growth  profile  (Figure  1d).  MRI  analysis  of  type  3  tumors  revealed 
heterogenous T2-weighted images which ended up with a large hypersignal in tumor cores, 
surrounded  by  a  hyposignal  ring.  Type  3  glioma  were  predominantly  observed  in  the 
cortex  (67%)  (Supplemental  Figure  1c).  In  agreement  with  their  growth  profiles,  11 
months after ENU exposure, Type 3 glioma have the highest mitotic index and Type 2 
glioma present 3 times more Ki67+ cells compared to Type 1 neoplasms (Figure 1e). 
Histological characterization showed that Type 1 tumors have homogenous cellular density 
within  tumor  bulks  with  a  normal  vascular  network  (Figure  1f).  Type  2  neoplasms 
exhibited a mixed population of normal rounded shape and hyperchromatic nuclei with an 
increased density of blood vessels (Figure 1g). Type 3 glioma exhibit malignant features 
with a large necrosis along with a very high developed vasculature (Figure 1h).
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Slowly proliferating rat glioma display features of oligodendroglioma.
We have previously shown that the most aggressive  rat glioma (Type 3) have histologic 
and immunophenotypic characteristics that resemble human glioblastoma [5]. Both rat and 
human glioblastoma are characterized by niches of tumorigenic cells which express nestin 
and IQGAP1 [4,5]. We here focused on further characterizing lower aggressive rat gliomas 
(Type 1 and Type 2) in order to identify the potential tumor initiating cells. 
In these non malignant  rat  tumors,  the  expression of IQGAP1 was restricted  to  tumor 
endothelial  cells  (Figure  2a).  The  strict  association  of  IQGAP1 immunoreactivity  with 
tumor  endothelial  cells  also  characterized  low-grade  and  high  grade  human 
oligodendroglioma  [5].   In  addition,  rat  tumor  cells  had  a  uniform immunophenotype 
characterized  by  intense immunoreactivities  for the cell  surface  NG2 proteoglycan and 
PDGFα-receptor (Figure 2b). NG2 and PDGFα-receptor have been previously shown to be 
specifically expressed in human oligodendroglioma but not in human glioblastoma [32]. 
Moreover, NG2+ tumor cells did homogenously express the nuclear transcription factors 
Olig2, Nkx2.2 and Sox10 of committed progenitor cells to oligodendroglial lineage [33,34] 
(Figure 2c).  Previous investigations  have demonstrated  that  the expression of  all  these 
markers  is  associated  with human oligodendroglioma [35-37].  None of the tumor cells 
expressed neither O4, a late marker of oligodendrocyte progenitor cells nor MBP, a marker 
of mature oligodendrocytes, in any of the rat low-grade induced-glioma (data not shown). 
In summary, histological and immunological analyses revealed that slowly proliferating rat 
brain tumors have features that resemble human oligodendroglioma.
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Early  low-grade glioma cells  are linked to slow-cycling  NG2-expressing precursor 
cells.
In  the  rodent  brain,  two populations  of  NG2-expressing cells  have been  reported  with 
different proliferation, differentiation and migration capacities [25,26,28]. NG2- and O4-
(late marker  of OPC) co-expressing cells  account for the biggest  pool of postnatal  and 
adult  dividing progenitor  cells  in brain parenchyma  and correspond to  oligodendrocyte 
progenitors contributing to oligodendrocytes, the myelinating cells of the central nervous 
system [25]. Another population of NG2-expressing cells in postnatal brain which possess 
a  low  proliferation  rate  and  a  limited  ability  to  differentiate  into  myelinating 
oligodendrocytes has also been identified [26].  In adult rat brain, NG2-expressing cells 
represent a major multipotential  progenitor population in the germinative subventricular 
zone (SVZ) and rostral  migratory stream (RMS) that gives rise to oligodendrocyte  and 
neurons  [27-29].  In  the  RMS,  these  cells  are  concentrated  within  migrating  chains  of 
proliferating βIII tubulin+ neuroblasts [28](Figure 3a). This specific NG2 cell population is 
characterized  by  few processes  and  the  nuclear  expression  of  Nkx2.2  [28]  and Sox10 
(Figure  3b).  In  contrast  to  parenchymal  NG2+/O4+  OPC and  migrating  βIII  tubulin+ 
neuroblasts, NG2+ precursor cells present within the SVZ and RMS are rarely labelled 
with the proliferation associated antigen Ki67 (Figure 3c). 
To  investigate  whether  low-grade  glioma  cells  could  interrelate  to  slow-cycling 
NG2+/Nkx2.2+/Sox10+  precursor  cells,  we  focused  on  early  hyperplasic  lesions  in  3 
month-old animals when brain tumors are not yet identifiable by MRI. In order to detect 
emerging micro-tumors, 20µm brain sections were performed from the olfactory bulb to 
posterior hippocampus. We then screened brain sections under the microscope to identify 
putative nascent neoplasms and stained them for NG2 and counterstained with DAPI to 
find any abnormal cell densities (Figure 4a and Supplemental Figure 2a). In Figure 4 we 
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selected early hyperplasic lesions emerging from the germinative rostral migratory stream 
(RMS)  where  low  grade  oligodendroglioma-like  tumors  preferentially  arose  from 
(Supplemental  Figure 1).  Tumor cells  were homogenously expressing NG2 (Figure 4a) 
Sox10 (Figure 4b) and Nkx2.2 (Figure 4c). We next compared the mitotic activity of tumor 
cells  with  adjacent  migrating  neuroblasts.  Data  show that  no  more  than  5% of  NG2-
expressing cells did express Ki67 antigen compared to migrating βIII tubulin+ neuroblasts, 
suggesting that low-grade glioma cells are allied to slow-cycling NG2-,Nkx2.2-, Sox10-
positive precursor cells (Figure 4d and 4e). These observations were consistent in all early 
hyperplasic  lesions  (n=15)  found  in  3  month-old  animals  (n=10)  irrespective  of  their 
location (Supplemental Figure 2). 
Low grade glioma-derived cells are compromised in their differentiation abilities. 
To  further  characterize the  NG2 cell  population  present  within  rat  induced  low-grade 
glioma, we next addressed their in vitro properties. Several attempts to grow cells from 6-7 
months  low proliferating  glioma  as  neurospheres  or  as  monolayers  were  unsuccessful 
suggesting that cell-cell contacts and signals from environment are crucial for tumor cells 
to survive and/or proliferate. Therefore, to analyze what properties these tumoral NG2+ 
cells could have in vitro, we cultured tumor explants in media supplementad with PDGF 
and bFGF to promote multipotent oligodendroglial progenitor proliferation [38]. After 6 
days in proliferative conditions, glioma cells continued to express NG2 (Figure 5a-b) and 
Nkx2.2 (Figure  5a).  While  cells  migrated  away from core  explants,  they  changed  cell 
immunophenotype and proliferation characteristics.  Migrating cells started to express late 
OPC markers  O4 (Figures  5b) and A2B5 (Supplemental  Figure 3).  About 30% of the 
migrating cells acquired O4+ phenotype (Figure 5c). Cells that migrated out of the explant 
also started dividing faster as 30% of the migrating cells became Ki67+ (Figure 5d and 
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Supplemental Figure 3), compared to less than 5% in original low grade tumors  in vivo 
(Figure  1e).  This  suggests  that within  the  tumor  mass,  NG2+ cells  are  maintained  in 
undifferentiated  and  non  proliferative  states  but  can  acquire  immunological  and  fast 
replication  characteristics  of  O4+ late  OPC in  determined  culture  conditions.  We next 
addressed whether tumor cells  are able  to fully differentiate  along the oligodendroglial 
lineage by culturing glioma explants in differentiation medium where PDGF and bFGF are 
replaced by T3 and forskolin [39]. After 6 days in these specific culture conditions the 
number of O4+ cells in glioma explant cultures did not significantly increased (Figure 5c) 
while proliferation slightly decreased (Figure 5d). Moreover, no MBP+ cells were detected 
(data not shown), pointing out that tumoral NG2+ cells can acquire OPC features but fail to 
fully  differentiate  into  oligodendrocytes.  Conversely,  in  such  culture  conditions, 
oligodendrocyte  progenitors  derived  from  newborn  rat  brains  sequentially  lost  NG2 
immunoreactivity and started expressing late OPC markers (i.e A2B5 and O4) after 3 days 
in vitro (Supplemental Figure 4a). By 6 days, some OPC matured into oligodendrocytes as 
they express the myelin basic protein (MBP) (Supplemental Figure 4b). 
Postnatal NG2+ cells can behave as multipotential precursor cells in vivo and in vitro and 
contribute  to  both  gliogenesis  and  neurogenesis  [27-29]-[27,30]. To further  investigate 
whether  tumoral  NG2+ cells  have  such  multipotential  capabilities  we  cultured  glioma 
explants in serum-containing medium for a week. Results show that glioma NG2+ cells 
could stably co-express both astrocyte marker GFAP and neuroblast marker βIII-tubulin 
while they were still  expressing NG2 and Nkx2.2 markers (Figure 5e-f).  Such aberrant 
patterns  of  expression  were  independent  of  culture  conditions.  These  observations 
emphasize  the  transformed  character  of  these  NG2-expressing  tumoral  precursor  cells. 
Overall, these findings suggest that ENU preferentially targets NG2+ multipotent precursor 
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cells which results in an impairment and/or aberrant differentiation of their progeny rather 
than an increase in cell proliferation.
 
A few tumoral NG2+ cells are resistant to radiations.
Currently, therapies for human low-grade gliomas include observation, resection, radiation 
and chemotherapy. Radiotherapy extends survival but total remissions are rarely observed 
[40]. In order to determine the response of ENU-induced glioma to radiotherapy, five rats 
aged of 6 months and carrying low grade glioma were irradiated with a 15 Gy dose in 
whole brain hemispheres and followed up by MRI for up to 4 months after treatment. From 
MRI examination,  three rats  showed an apparent total  tumor regression 137 days  upon 
treatment  (Figure  6a-b).  Nevertheless,  the  histological  analysis  of  irradiated  tissues 
revealed  the  presence  of  remnant  tumor  cells  which  resisted  radiations  (Figure  6c-d). 
Among  those  surviving  cells,  87.6%  and  82.6%  express  Sox10  and  Olig2  markers 
respectively (Figure 6d). On the other hand, the stem cell markers, nestin and IQGAP1 
were still  exclusively present in blood vessels. These results suggest that rat  low grade 
glioma are in their majority radiosensitive, as observed for human oligodendroglioma, but 
some radio-resistant tumor cells persist and could be responsible for tumor recurrence. 
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Here  we  used  a  rat  model  that  develops  glioma  following  in  utero exposure  to  the 
mutagenesis  agent  N-ethyl-N-nitrosurea to investigate  the potential  origin of low-grade 
glioma. Although genetic mutations induced by ENU may be difficult to identify [24], this 
model provides useful insights about the early events that precede glioma formation and 
may thus be helpful to identify cells of origin for glioma. Rat low grade gliomas represent 
the  major  asymptomatic  neoplasic  lesions  (67%)  6  months  after  exposure  to  ENU. 
Longitudinal imaging analysis revealed that after a latency period of 6 months, some low 
grade glioma developed into more aggressive tumors (referred as Type 2). Taking into 
account that both tumor subtypes developed with high frequency in the same brain regions 
(Supplemental  Figure  1),  it  is  likely  that  they  might  have  the  same  origin.  Such 
modifications in tumor characteristics could be due to changes in tumor environment or to 
additional mutations. 
Within slowly dividing gliomas tumor cells homogenously expressed the same markers, 
including cell surface markers NG2 and PDGFα-R and nuclear transcription factors Olig2, 
Sox10 and Nkx2.2.transcription factors (Figures 2 and Supplemental Figure 2), involved in 
embryonic OPC specification [33,34].  In situ, tumor cells did not express O4, a surface 
marker of late OPC during postnatal development [41] as well as specific of adult OPC 
which  are  scattered  in  the  all  brain  parenchyma  [25,42,43].  Several  studies  have 
demonstrated  the  heterogeneity  of  NG2+  cell  population  with  different  proliferation 
features and differentiation capacities [26,42,44]. Moreover, a population of multipotent 
NG2+  precursor  cells  that  is  able  to  produce  both  glial  cells  and neurons  has  been 
identified [27-30,33,38,39,45]. We propose that these multipotent NG2 precursor cells can 
be a preferential target for ENU-mutagenesis. As we could expect from developmentally-
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deregulated cells with multipotential competence,  in vitro tumor cells were characterized 
by aberrant co-expressions of several cell lineage antigens (Figure 5). Longitudinal MRI 
imaging revealed that rat low grade glioma have a slow and linear growth phase suggesting 
that  the  initial  transformation  process  is  not  primarily  associated  with  a  gain  in 
proliferation capacity. We can envision that ENU mutagenesis modified genes that control 
either  the  self-limiting  extension,  or  the differentiation  capacities  of  multipotent  NG2+ 
precursor cells, or both, to initiate glioma formation. We, indeed, have clearly shown that, 
in vitro,  tumor cells  are severely compromised in their terminal  differentiation abilities 
(Figure 5). These results are in agreement with a recent study showing that immortalized 
neural  progenitor  cells  derived from ENU-treated rats  were unable to  differentiate  into 
neural lineages [31].  Finally, we have demonstrated that changes in cell-cell interactions 
and  environment  cues  induced  drastic  immunophenotype  modifications  as  well  as  an 
increase in cell proliferation of tumor cells derived from rat low grade glioma (Figure 5 
and  Supplemental  Figure  3).  This  highlights  that  the  homogenous  character  and  non 
proliferative features identified in rat low grade glioma in situ are likely due to the tumor 
microenvironment. 
In  summary,  taken together our results strongly suggest that  multipotent  NG2-expressing 
glial  precursor  cells  are  a  new potential  glioma  cell  initiating  population  in  N-ethyl-N-
nitrosourea-induced gliomagenesis. Another possible scenario is that an initial mutation has 
occurred within a true stem cell early on and that mutation is only revealed in downstream 
precursor cells. In order to address the presence of stem-like cells in rat low grade glioma we 
subjected rat brains to radiations (Figure 6). We observed that some tumor cells were still 
present upon irradiation. These cells retained characteristics of NG2+ precursor cells and did 
not express the neural stem cell markers nestin and IQGAP1. 
17
 at INSERM






Moreover, in contrast to glioblastoma [5], we were not able to produce neurospheres from 
rat ENU-induced low grade glioma, pointing out the absence of typical cancer stem-like 
cells within these tumors. Given that tumor sizes are quite small and that tumoral NG2+ 
cells cannot be expanded in vitro, testing the tumorigenic potential of these cells is truly 
challenging.  Since low grade glioma homogeneously express the NG2 marker  and that 
cell-cell contacts and signals from environment seem to be crucial for survival of NG2+ 
tumor cells, another way  to address the tumorigenicity of those cells might be to directly 
transplant tumor pieces into different brain regions of immunocompromised mouse strains. 
Overall  this  makes  the  cancer  stem cell  hypothesis  as  the  origin  of  rat  ENU-induced 
oligodendroglioma quite unlikely. 
This study might also  open up new perspectives for understanding several features of the 
human disease. Low grade rat gliomas showed histological characteristics that are similar to 
human  oligodendroglioma.  Those  includes  homogenous  cellularity,  uniform  cells  with 
minimal  process  formation,  regular  round  nuclei,  and  arborizing  capillary  network  that 
stained with collagen IV and IQGAP1 antibodies [5]. Rat tumor cells also express sets of 
genes (i.e NG2, PDGFα-R, Olig2, Sox10 and Nkx2.2) that are also preferentially found in 
human  oligodendroglioma  and  oligoastrocytoma.  [32,35,37].  The  capability  for  rat 
oligodendroglioma-derived cells to express mosaic immunophenotypes when grown in vitro 
(Figure 5) could provide an explanation about the cell heterogeneity observed in high grade 
human oligodendroglioma which often makes their respective classification difficult or even 
impossible  [7].   Rat  glioma cells  were able  to  express  the  neuronal  marker  βIII-tubulin 
(Figure  5f)  which  would  explain  why  oligodendroglioma  frequently  display 
immunohistochemical  and  ultrastructural  features  of  neuronal  cells  [46].   Moreover,  we 
demonstrated  that  rat  glioma  cells  exhibit  aberrant  co-expression  of  both astrocytic  and 
oligodendroglial  cell  lineage  markers  (Figure  5e),  thus  providing  a  rationale  for  similar 
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genetic signatures identified in both astrocytic and oligodendrocytic components in mixed 
human  oligoastrocytoma  [47].  Although one  has  to  be  cautious  before  extrapolating  rat 
models  to  human  pathologies,  similarities  between  rat  low  grade  glioma  and  human 
oligodendroglioma might provide clues to explain some characteristics of the human disease 
and further understand how glioma emerge and develop over time in order to design new 
therapies aiming at curing brain tumors. 
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Figure 1: Visualization and development of rat ENU-induced glioma
a-c: Typical T2-weighted MR images of the follow-up of 3 different types of ENU-induced 
tumors up to 11 months along the apparent diffusion coefficient (ADC) measured at 11 
months.  ENU-induced tumors  are  classified as Type  1 (a),  Type 2 (b) and Type 3 (c) 
glioma according to their location and evolution.  Initial  lesions are circled in white. In 
panel a, arrow heads point to a typical low-grade type 1 glioma. Bar= 4mm.
d: Different volume quantifications from MRI scans allowed us to distinguish 3 typical 
growth profiles over a period of 11 months (n=21 for type 1, n=6 for type 2 and n=6 for 
type 3). Type 3 glioma accounts for the most aggressive and malignant brain tumors. Error 
bars represent SEM. *, p<0.05 vs type 1, $, p<0.01 vs Type 2 (Two-Way Anova)
e: Quantification of proliferating rate in Type 1, 2 and 3 induced glioma in 11-month-old 
rats.  Tumor slices were stained with Ki-67 antibodies and counterstained with Hoechst 
marker. Student’s t-test was applied, * P-Value < 0.05 and ** P-Value < 0.01 compared to 
Type 1 glioma. 
f-h:  Histological  analysis  of  rat  ENU-induced Type  1 (f),  Type  2 (g),  and Type  3 (h) 
glioma  stained  with  hematoxylin  and  eosin  (upper  panels)  and  immunostained  with 
collagen IV to visualize blood vessels (lower panels). In f, the dashed line circles the tumor 
bulk. Bars=200µm (a); Bar=100µm (b and c).
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Figure 2: Immunohistochemical characterization of rat low-grade glioma.
a: Microscope analysis of a low-grade tumor of a 9-month-old rat stained with IQGAP1 
antibodies  and  counterstained  with  Hoechst  (DNA).  IQGAP1 is  only  present  in  blood 
vessels. Bar= 50 μm. 
b:  Confocal  microscope  analysis  of  a  low-grade  tumor  of  a  9-month-old  rat  co-
immunostained  with  NG2  (green)  and  PDGFα-R  (red)  antibodies.  Merge  image 
demonstrate a colocalization of NG2 and PDGFα-R markers. Bar= 20μm. 
c:  Confocal  microscope  analysis  of  a  low-grade  tumor  of  a  9-month-old  rat  co-
immunostained for the nuclear markers Olig2, Nkx2.2 and Sox10 as indicated (red), NG2 
(green) and Hoechst (DNA, blue). Bar=10μm.
Figure 3: Identification of slow dividing NG2+ precursor cells in the rostal migratory 
stream of 3 month-old rats.
a-c: Confocal analysis of coronal rat brain sections in the proximal (a and b) and the most 
distal part (c) of the RMS area double stained for  NG2 (green) and βIII-tubulin (red) (a; 
Bar= 40μm); triple stained  for NG2 (green) Sox10 (red) and DNA (blue) (b; Bar= 10μm); 
or double stained  for NG2 (green) and Ki-67 (red) (c; Bar= 20μm).  
Figure 4: Characterization of slow dividing NG2+ glioma cells in early hyperplasic 
lesions in the rostal migratory stream.
a: Brain sections of 3-month old rats stained with NG2 antibodies and counterstained with 
Hoechst (DNA) to visualize emerging ENU-induced tumors in the RMS, Bar=200μm. 
b-c: Confocal analysis of low-grade glioma located within the RMS and double stained for 










d-e: Confocal analysis of a low-grade glioma located within the RMS and double stained 
for NG2  (green)  and βIII-tubulin  (red)  or  for  NG2  (green)  and  Ki-67  (red)  (d-e; 
Bar=80μm). 
Figure  5:  Immunocytochemical  characteristics  of  rat  low-grade  glioma-derived 
explants
a: Tumor-derived explants in proliferating conditions in presence of both PDGF and bFGF 
were double immunostained with NG2 and Nkx2.2 antibodies. Bar=50μm.
b: Microscope observation of a glioma-derived explant grown 6 days in culture medium 
supplemented with PDGF and bFGF and double immunostained with NG2 (green) and O4 
(red) antibodies. Bar=200μm
c: Quantification of O4+ cells of 6 day-explant cultures in proliferating (PDGF + bFGF) 
and differentiating (T3 + forskolin) conditions.
d:  Quantification  of  Ki-67+  cells  of  6  day-explant  cultures  in  proliferation  and 
differentiation  media.  Results  show a  small  decrease  of  proliferation  in  differentiating 
conditions. * Student's T-Test, P-Value<0.05.
e-f: Tumor cells migrating away from glioma explants  in culture medium supplemented 
with PDGF and bFGF were double immunostained with Nkx2.2 (red) and GFAP (red) 
antibodies  (e),  or  double  immunostained  with  NG2  (green)  and  βIII-tubulin  (red) 










Figure 6: Response of low-grade glioma to radiations
a: MRI follow-up of a 0,8 mm3 low-grade glioma located in the corpus callosum of a 6 
month-old rat, before (- 4 days) and after irradiation from 4 to 137 days. At day 0, rats 
were irradiated with a single dose of 15 Gy. 
b: Regression curve of the low-grade tumor shown in panel a. By 10 days, the tumor size 
decreases by about 25% to reach 0,060 mm3 at day 137.
  c: Hematoxylin and eosin stainings revealed a residue of tumorigenic tissue in the corpus 
callosum at day 137 post irradiation. Bar=200μm.
d:  Radio-resistant  tumor  cells  strongly expressed Olig2 and Sox10 but  did not express 

















































































Supplemental figures legends: 
Supplemental figure 1: 
Spatial distribution within the brain parenchyma of the 3 major subtypes of ENU-induced 
brain  tumors,  such  as  low  grade  oligodendroglioma-like  (type  1),  high  grade 
oligodendroglioma-like  (type  2)  and  high  grade  glioblastoma-like  (type  3).  These 
quantifications  were  performed  from two independent  experiments  including  MRI and 
histological  analyses  (n=40  tumors).  LV/SVZ:  Lateral  ventricule/subventricular  zone, 
RMS: Rostral migratory stream. 
Supplemental Figure 2: Characterization of early low grade glioma.
a: Brain sections of 3-month old rats stained with NG2 antibodies and counterstained with 
Hoechst (DNA) to localize emerging ENU-induced tumors in different brain regions, such 
as the rostral migratory stream (RMS), the subventricular zone (SVZ), the corpus callosum 
(CC) and the cortex. Bar= 200µm. 
b:  Low grade glioma express  oligodendrocyte  progenitor  cell  markers.  Early neoplasm 
located in the corpus callosum (CC), the RMS and the cortex were co-immunostained with 
NG2  antibodies  and  with  Nkx2.2  (red),  Sox10  (green)  and  Olig2  (green)  antibodies 
respectively. Bar=50μm. 
c: Early neoplasm emerging from the striatum immunostained with Ki67 antibodies (red) 
and counterstained with Hoechst (DNA). Bar=50μm. 
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Supplemental  Figure  3.  Immunocytochemical  characteristics  of  low grade glioma-
derived explants.
Tumor-derived explants in  proliferating conditions were triple immunostained with NG2 
(green), Ki67 (purple) and A2B5 (red) antibodies and counterstained with Hoechst (DNA, 
blue). Pictures focused on cells migrating out the tumor bulk (dashed line). Bar=50μm.
Supplemental figure 4. Characterization of new born rat oligodendrocyte progenitor 
cell (OPC) cultures.
a: Rat brain OPC grown in proliferation medium containing bFGF and PDGF (left panels, 
control),  or  left  72h in  differentiation  medium (right  panel)  were  immunostained  with 
NG2, A2B5 or O4 antibodies as indicated.
b:  Rat brain OPC grown 6 days  either  in proliferation medium (left  panel,  control),  or 
cultured in differentiation medium (right panel, 6 days-diff) stained for the oligodendrocyte 
marker, myelin basic protein (MBP). 
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